Strain AI vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Strain AI

by Exo

EchoNext

by Pathway Labs

AI Verdict

Both Strain AI and EchoNext are FDA-cleared cardiology AI tools that aid in detecting heart conditions, including heart failure. However, Strain AI focuses on analyzing cardiac ultrasound images for Global Longitudinal Strain measurements, while EchoNext analyzes standard ECGs to detect hidden structural heart disease. Therefore, the choice between them depends on whether the diagnostic workflow involves ultrasound image analysis or ECG interpretation.

Choose Strain AI if…

Choose Strain AI if your cardiology practice or oncology department requires precise, on-device analysis of cardiac ultrasound images to measure Global Longitudinal Strain (GLS). This tool is ideal for real-time assessment of heart function in adult patients, particularly for detecting conditions like heart failure and cardiotoxicity without needing an internet connection. It integrates with existing ultrasound devices to provide quantitative strain measurements, aiding in diagnostic evaluation.

View Strain AI →

Choose EchoNext if…

Choose EchoNext if your practice, from major hospitals to community settings, needs an FDA-cleared AI tool to screen for hidden structural heart disease using standard ECGs. This solution is best suited for early detection of conditions such as heart failure, valve disease, and pulmonary hypertension, offering a non-invasive diagnostic support that can flag high-risk patients for further evaluation like an echocardiogram. It is deployed through the OpenEvidence clinical decision support platform and is designed for broad accessibility.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Strain AI	EchoNext
Pricing	Contact for pricing	Starts at $600/month
Deployment	On-device AI, operates without internet connection.	Available through the OpenEvidence clinical decision support platform.
BAA Available	Yes AI-estimated	Yes AI-estimated
FDA Status	Yes AI-estimated	Yes AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Strain AI

Strain AI operates on-device and without an internet connection, offering real-time insights directly at the point of care. This deployment model suggests a more seamless and immediate user experience compared to EchoNext, which is available through a separate clinical decision support platform, potentially adding an extra step to the workflow.

Clinical Value

EchoNext

EchoNext has demonstrated superior accuracy in detecting structural heart disease from ECGs compared to cardiologists, even those assisted by AI. It has also been credited with leading to the first heart transplant attributable to AI-based disease detection. While Strain AI provides valuable GLS measurements, EchoNext's ability to identify a broader range of hidden structural heart diseases from a more common and inexpensive test (ECG) offers a potentially greater impact on early detection and patient outcomes.

Pricing & Value

EchoNext

EchoNext provides transparent tiered pricing starting at $600/month, including details on implementation fees and discounts. Strain AI, in contrast, requires contacting for pricing, which offers less transparency and makes it harder for potential customers to assess its value proposition upfront. Price transparency is increasingly important in healthcare AI.

Enterprise Readiness

EchoNext

EchoNext is designed for broad access, from major hospitals to community practices, and is deployed through the OpenEvidence clinical decision support platform, which is used by 650,000 U.S. physicians. This wide deployment and target audience suggest a robust enterprise strategy and established integration capabilities. Strain AI's on-device deployment is innovative but its enterprise scalability and integration with existing hospital systems are not as clearly articulated.

Innovation

Tie

Both tools demonstrate significant innovation in their respective domains. Strain AI's real-time, on-device AI for GLS analysis on handheld ultrasound is a notable advancement in point-of-care diagnostics. EchoNext's ability to detect a wide range of hidden structural heart diseases from standard ECGs, outperforming human cardiologists, represents a groundbreaking approach to early screening for cardiovascular conditions.

Support & Docs

Tie

Neither tool provides explicit details about their support and documentation in the given information. Without further information on service level agreements, training programs, or comprehensive documentation portals, it is not possible to definitively pick a winner in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Strain AI	EchoNext
Name	Strain AI	EchoNext
Company	Exo	Pathway Labs
Description	AI-powered medical software that analyzes cardiac ultrasound images to measure Global Longitudinal Strain (GLS), aiding physicians in assessing heart function and detecting conditions like heart failure and cardiotoxicity in adult patients.	AI tool that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Key Features	Analyzes cardiac ultrasound images, Measures Global Longitudinal Strain (GLS), Aids in assessing heart function in adult patients, Integrates with existing ultrasound devices, Provides quantitative strain measurements, Supports diagnostic evaluation without manual image interpretation, Delivers real-time, on-device AI insights, Assists in detecting heart failure (CHF, HFpEF, HFrEF) and hypertrophy	AI-powered ECG analysis, Detection of hidden structural heart disease, Identifies heart failure risk, Screens for valve disease, Detects pulmonary hypertension indicators, Utilizes standard 12-lead ECGs, FDA-cleared technology, Non-invasive diagnostic support
Categories	Cardiology AI, Radiology & Imaging AI	Cardiology AI, Clinical Decision Support & Reference, Lab & Diagnostics
Specialties	Cardiology, Oncology, Radiology	Cardiology, Family Medicine, Hospital Medicine, Internal Medicine

Videos

Demos, reviews, and walkthroughs featuring Strain AI and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do Strain AI and EchoNext integrate into existing clinical workflows, and what is the learning curve for physicians?

Strain AI, being an on-device AI for cardiac ultrasound, integrates with existing ultrasound devices and provides real-time insights, suggesting a direct incorporation into echocardiography workflows. EchoNext analyzes standard ECGs and is available through the OpenEvidence clinical decision support platform, indicating integration into routine ECG interpretation and broader clinical decision-making. The learning curve for Strain AI might involve familiarization with its automated GLS measurements, which aim to reduce variability and manual interaction. For EchoNext, physicians would learn to interpret its AI-powered flags for structural heart disease from ECGs, which has been shown to outperform cardiologists in accuracy.

What are the key differences in accuracy and sensitivity between Strain AI's GLS measurements and EchoNext's ECG analysis for detecting heart conditions?

Strain AI focuses on measuring Global Longitudinal Strain (GLS) from cardiac ultrasound images, which is a sensitive indicator for detecting subtle myocardial dysfunction and conditions like heart failure and cardiotoxicity. EchoNext analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, and has shown higher accuracy (77%) than cardiologists (64%) in identifying structural heart problems from ECGs alone. While both are highly accurate, Strain AI provides quantitative strain measurements from ultrasound, offering a detailed view of myocardial mechanics, whereas EchoNext acts as a screening tool to identify patients who warrant further evaluation with an echocardiogram.

Given their different diagnostic approaches, for which specific patient populations or clinical scenarios would each tool be most suitable?

Strain AI, with its focus on Global Longitudinal Strain from ultrasound, would be particularly suitable for adult patients undergoing cardiac ultrasound for assessing heart function, detecting early signs of heart failure (CHF, HFpEF, HFrEF), and monitoring cardiotoxicity, especially in oncology patients. EchoNext, by analyzing standard ECGs to detect hidden structural heart disease, is ideal for broad screening in various settings, from major hospitals to community practices, to identify patients at high risk for conditions like heart failure, valve disease, and pulmonary hypertension who may require further imaging.

What kind of customer support and training can physicians expect for each tool, and how does this impact time-to-value?

While specific details on support quality are not provided for Strain AI, its on-device deployment suggests that support might involve technical assistance for the ultrasound integration and software updates. For EchoNext, its availability through the OpenEvidence platform implies that support and training could be facilitated through that established clinical decision support ecosystem. The time-to-value for AI tools is influenced by factors like data readiness, organizational alignment, and project scope, with small businesses potentially seeing initial results in 3-4 months. Both tools aim to streamline diagnostic processes, which inherently contributes to faster time-to-value by improving efficiency and potentially reducing diagnostic delays.

Beyond HIPAA, what are the security and audit-trail features of Strain AI and EchoNext, especially concerning patient data handled by on-device vs. platform-based AI?

Strain AI operates with on-device AI without an internet connection, which inherently limits external data transmission risks, focusing security on the device itself. EchoNext, deployed through the OpenEvidence platform, would rely on the platform's security posture beyond HIPAA, which for clinical decision support platforms typically includes robust data governance and security protocols for handling patient data. While specific audit-trail features are not detailed for either, AI tools in healthcare are generally expected to have mechanisms for tracking data analysis and decisions for accountability and regulatory compliance.

How do these tools facilitate multi-site rollouts, and are there any considerations for standardization across different clinical environments?

Strain AI's on-device nature suggests that multi-site rollout would involve deploying the AI software on each compatible ultrasound device, with standardization potentially managed through consistent software versions and training across sites. EchoNext's deployment through the OpenEvidence platform could simplify multi-site rollouts by leveraging an existing, widely used clinical decision support infrastructure, which is designed for broad access across various practice settings. For both tools, ensuring consistent performance across diverse patient demographics and clinical contexts is crucial for effective multi-site implementation.

Are there publicly available customer references or case studies that demonstrate the real-world impact and physician satisfaction with Strain AI or EchoNext?

For Strain AI, the provided information does not include specific publicly available customer references or case studies. For EchoNext, it has been highlighted in a peer-reviewed case published in Nature Medicine where it flagged severe, undiagnosed heart failure in a patient who ultimately received a successful heart transplant. Additionally, Pathway Labs is partnering with OpenEvidence, a platform used by a significant number of U.S. physicians, to expand access, suggesting real-world adoption and potential for customer feedback.